---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-070346"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T13:22:54.984034+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro reports record Q1 revenue $8.5M, consumables up 104% YoY

## Summary
- Q1 revenue $8.5M (record), up 11% YoY; consumable product revenue grew 104% to $5.5M.
- Neurosurgery navigation therapy revenue up 70% to $3.3M; biologics & drug delivery revenue up 9% to $4.7M.
- Gross margin 60% (vs 59%); opEx up 29% to $11.3M on higher R&D and headcount.
- Cash $12.4M at Mar 31 (down from $20.1M Dec 2024); credit facility secured with Oberland Capital.
- FY 2025 revenue guidance reaffirmed at $36M-$41M; FDA clearance for ClearPoint 3.0 software.

## SEC filing metadata
- accession: 0000950170-25-070346
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000095017025070346/0000950170-25-070346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000095017025070346/clpt-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-070346
- JSON: https://secwatch.observer/filing/0000950170-25-070346.json
- Plain text: https://secwatch.observer/filing/0000950170-25-070346.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.